Hepatitis C, Hepatitis C virus, Internal medicine, Immunology and Virology are his primary areas of study. His studies deal with areas such as Epidemiology, Cohort study, Incidence, Intensive care medicine and Substance abuse as well as Hepatitis C. His work deals with themes such as Viral disease, Disease burden and Developed country, which intersect with Hepatitis C virus.
His Internal medicine course of study focuses on Ribavirin and Alpha interferon. His Immunology study incorporates themes from Pharmacotherapy and Disease. His research investigates the connection between Virology and topics such as Reimbursement that intersect with problems in Paritaprevir, Ritonavir, Dasabuvir and Hepatitis.
His scientific interests lie mostly in Hepatitis C virus, Hepatitis C, Virology, Internal medicine and Immunology. The Hepatitis C virus study combines topics in areas such as Incidence, Viral load, Drug and Cohort. His studies in Incidence integrate themes in fields like Transmission and Environmental health.
His Hepatitis C study combines topics in areas such as Odds ratio, Epidemiology, Family medicine, Liver disease and Prospective cohort study. His study focuses on the intersection of Internal medicine and fields such as Ribavirin with connections in the field of Alpha interferon. Jason Grebely studies Immunology, namely Coinfection.
Jason Grebely spends much of his time researching Hepatitis C virus, Hepatitis C, Internal medicine, Environmental health and Family medicine. His Hepatitis C virus research is under the purview of Virology. His Hepatitis C study also includes
His study in Internal medicine is interdisciplinary in nature, drawing from both Pibrentasvir, Glecaprevir, Drug and Sofosbuvir. His Environmental health research is multidisciplinary, relying on both Meta-analysis and Systematic review. His Family medicine research is multidisciplinary, incorporating perspectives in Addiction medicine and Phlebotomy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif.
The Lancet Gastroenterology & Hepatology (2017)
Epidemiology and natural history of HCV infection
Behzad Hajarizadeh;Jason Grebely;Gregory J. Dore.
Nature Reviews Gastroenterology & Hepatology (2013)
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
Louisa Degenhardt;Amy Peacock;Samantha Colledge;Janni Leung.
The Lancet Global Health (2017)
Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals
Natasha K. Martin;Peter Vickerman;Jason Grebely;Margaret Hellard.
Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.
Soumitri Barua;Robert Greenwald;Jason Grebely;Gregory J. Dore.
Annals of Internal Medicine (2015)
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
Jason Grebely;Kimberly A Page;Rachel Sacks-Davis;Martin Schim van der Loeff.
Global statistics on alcohol, tobacco and illicit drug use: 2017 status report
Amy Peacock;Amy Peacock;Janni Leung;Sarah Larney;Sarah Larney;Samantha Colledge.
Treatment of Hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis
Esther J Aspinall;Stephen Corson;Joseph S Doyle;Joseph S Doyle;Joseph S Doyle;Jason Grebely.
Clinical Infectious Diseases (2013)
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Reem Waziry;Behzad Hajarizadeh;Jason Grebely;Janaki Amin.
Journal of Hepatology (2017)
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial
Gregory J. Dore;Frederick Altice;Alain H. Litwin;Olav Dalgard.
Annals of Internal Medicine (2016)
Journal of Hepatology
(Impact Factor: 30.083)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: